Charles River Laboratories is predicting 2025 to be as tough as last year for CDMOs as pharma customers continue to cut costs ...
Four Lykos Therapeutics board members have stepped down and another departed last month, the aftermath of a stalemate over how to finance the psychedelic company's clinical future.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback